Inhibitory Interneuron Precursors for Hypothalamic Glycemia Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current medical therapies for diabetes, particularly type 2 diabetes, have failed to effectively address the underlying cause of hyperglycemia, leading to significant health complications.

Innovation Solution

Delivering inhibitory interneuron precursor cells, derived from embryonic or induced pluripotent stem cells, into the arcuate nucleus of the hypothalamus to modulate the activity of neurons associated with hyperglycemia, thereby reducing abnormal hyperactivity and ameliorating hyperglycemia.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If conventional anti-diabetic medications are used to treat hyperglycemia, then blood glucose levels can be temporarily reduced, but the underlying cause of diabetes remains unaddressed and outcomes do not improve

Engineering Contradiction:

Improveblood glucose levelsVSAvoiddisease outcome improvement

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The invention extracts and addresses the root cause of diabetes by targeting abnormal neuronal activity in the arcuate nucleus, rather than merely treating the symptom (hyperglycemia). By delivering inhibitory interneuron precursors to modulate neuronal excitability at its source, the treatment tackles the underlying pathology while conventional drugs only manage blood glucose levels.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

Instead of treating diabetes by targeting peripheral insulin-producing or insulin-sensitive tissues (the conventional approach), this invention inverts the strategy by targeting the central nervous system, specifically the arcuate nucleus in the hypothalamus. This reversal of the treatment approach allows addressing the root cause of hyperglycemia through central neural control rather than peripheral metabolic pathways.

Inventive Principle:

Principle #13The other way round (Inversion)

2Duration of action of stationary object

If inhibitory interneuron precursors are delivered into the arcuate nucleus to address the underlying cause of diabetes, then long-lasting reduction inhyperglycemia is achieved, but the treatment complexity increases

Engineering Contradiction:

Improveduration of hyperglycemia reductionVSAvoidtreatment delivery complexity

Core Design Contradiction:

Duration of action of stationary objectVSDevice complexity

Solution Approach 1:

The invention uses preliminary action by delivering inhibitory interneuron precursors (rather than mature neurons) to the arcuate nucleus. These precursors then mature in situ and establish long-term inhibitory connections, providing sustained therapeutic effect. This preliminary delivery of precursor cells simplifies the overall treatment compared to delivering complex mature neuronal circuits.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The inhibitory interneuron precursors act as intermediaries between the administered therapy and the target neuronal circuits. These precursors differentiate into mature inhibitory neurons that mediate the suppression of abnormal excitatory activity in the arcuate nucleus, providing a bridge between the treatment and the pathological process.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250319137A1Inhibitory interneuron treatment methods, uses, and compositions for diabetes

Publication Date: 2025.10.16 DIGNITY HEALTH

AI summary

Disclosed herein are compositions, methods of treatment, and uses of inhibitory interneuron precursors, derived from the brain's medial ganglionic eminence, or differentiated from iPSC or ESCs, for the treatment of pre-diabetes or diabetes. In some embodiments, compositions including inhibitory interneuron precursors are transplanted into the arcuate nucleus of the hypothalamus region of the brain, to treat, for example, diabetes, such as, type-2 diabetes. In further embodiments, inhibitory interneuron precursors are used in the manufacture of a medicament for the treatment of diabetes, for example, type-2 diabetes.